Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3703 | Standard Dissemination Practice Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D019966 | Substance-Related Disorders NIH | 0.28 |
| D004630 | Emergencies NIH | 0.17 |
| D004194 | Disease NIH | 0.16 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the impact of (1) Implementation Facilitation (IF) on rates of provision of Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) treatment with referral for ongoing medication-assisted treatment (MAT) and the (2) effectiveness of IF on patient engagement in formal addiction treatment at 30 days.
Description: The primary implementation outcome will be evaluated assessing the rate of ED-initiated BUP therapy with referral for ongoing MAT over the 12 month period.
Measure: Implementation (Considered the Primary Outcome) Time: 12 monthsDescription: The primary effectiveness outcome is defined as the rates of patient engagement in formal addiction treatment on the 30th day post enrollment.
Measure: Effectiveness Time: 30 Days Post EnrollmentDescription: Fidelity will be measured using a critical action checklist relating to the provision of ED-initiated BUP with referral for ongoing MAT in eligible patients.
Measure: Implementation: Fidelity Time: Baseline Period (Baseline)Description: Fidelity will be measured using a critical action checklist relating to the provision of ED-initiated BUP with referral for ongoing MAT in eligible patients.
Measure: Implementation: Fidelity Time: IF Evaluation Period (18 months)Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT
Measure: Implementation: ED provider Readiness and Preparedness Ruler Score Time: Pre IF (Baseline)Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT
Measure: Implementation: ED provider Readiness and Preparedness Ruler Score Time: Post IF (6 months)Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT
Measure: Implementation: ED provider Readiness and Preparedness Ruler Score Time: post IF Evaluation Period (12 months)Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT
Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score Time: Pre IF (Baseline)Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT
Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score Time: Post IF (6 months)Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT
Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score Time: Post IF Evaluation Period (12 months)Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP
Measure: Implementation: Community Readiness and Preparedness Ruler Score Time: Pre IF (Baseline)Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP
Measure: Implementation: Community Readiness and Preparedness Ruler Score Time: Post IF (6 months)Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP
Measure: Implementation: Community Readiness and Preparedness Ruler Score Time: post IF Evaluation Period (12 months)Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP
Measure: Implementation: Community ORCA Score Time: Pre IF (Baseline)Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP
Measure: Implementation: Community ORCA Score Time: Post IF (6 months)Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP
Measure: Implementation: Community ORCA Score Time: post IF Evaluation Period (12 months)Description: Self-reported days of illicit opioid use (past 7 days) as measured by Time-Line Follow-Back methods at 30 days
Measure: Effectiveness: Opioid Use Time: 30 days post enrollmentDescription: Overdose event (past 30 days) captured by participant self-report, state medical examiner records, National Death Index and review of medical records
Measure: Effectiveness: Overdose Event Time: 30 days post enrollmentDescription: HIV risk taking behaviors (past 30 days) as measured by HIV Risk Taking Behavior Scale
Measure: Effectiveness: HIV Risk Time: 30 days post enrollmentDescription: All Healthcare Service Utilization Inpatient and Outpatient
Measure: Effectiveness: Healthcare Service Utilization Time: 30 days post enrollmentDescription: Rates of illicit opioid negative urines
Measure: Effectiveness: Illicit Opioid Urine Toxicology Time: 30 days post enrollmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports